In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold ...
In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.
Divided government in Washington reduces momentum for most-favored-nation drug pricing and weakens US leverage to push higher European list prices amid constrained public budgets. Differential (equity ...
CVS will create an independent retail pharmacy entity (~9,000 stores plus mail, MinuteClinic, Health100) while keeping payer–PBM–specialty assets integrated to optimize focus and capital allocation.
In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.
APIIC's Brian Doty says renovating shuttered US plants with advanced manufacturing is faster and cheaper than building new to reshore generics. Renovating idle domestic facilities, rather than ...
In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results